MFN2 and Charcot-Marie-Tooth disease type 2A1: Isogenic controls are particularly valuable in autosomal dominant diseases like CMT2A, where they can help dissect how the ratio of WT to mutant MFN2 influences disease expression, providing a robust platform to determine whether correcting a single allele is sufficient to rescue the phenotype and offering insights into gene dosage effects.